$ALLO News

Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target

Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript

Allogene Therapeutics Files Prospectus For $500M Offering

Allogene Therapeutics Q2 EPS $(0.13) Beats $(0.17) Estimate, Sales $4.640M Beat $2.222K Estimate

Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA's Regenerative Medicine Advanced Therapy, Fast Track Designations To Treat B-Cell Lymphoma

Allogene Therapeutics Publishes Data From Phase 1 TRAVERSE Trial Of ALLO-316 In Advanced Or Metastatic Renal Cell Carcinoma; Trial Shows 31% Confirmed Response Rate With Recommended Phase 2 Regimen; Robust Expansion And Tumor Infiltration Seen

Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation

Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript

Allogene Therapeutics Q1 2026 Earnings Call Transcript

Allogene Therapeutics Enters Termination Agreement With Overland Therapeutics On May 12, 2026; Terminates Exclusive License Agreement With Overland Therapeutics Effective May 12, 2026; No Termination Payments Made In Connection With Termination Agreement; To Hold About 3% Of Overland Equity After Surrendering Portion For No Consideration

Allogene Therapeutics Q1 EPS $(0.18) Beats $(0.19) Estimate

Allogene Therapeutics Receive South Korea, Australia Clearance To Expand Its Pivotal Phase 2 ALPHA3 Trial Of Cemacabtagene Ansegedleucel To Treat Patients With Large B-Cell Lymphoma

JP Morgan Upgrades Allogene Therapeutics to Neutral

Allogene Therapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and lowered its price target from $12 to $11.

Allogene Therapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and lowered its price target from $12 to $11.

HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $11

Jefferies Maintains Buy on Allogene Therapeutics, Raises Price Target to $10

Allogene Therapeutics shares are trading higher after the company announced a $175 million offering of 87.5 million shares at $2.00 per share.

Allogene Therapeutics Announces The Publication Of Pre-Clinical Data For ALLO-329, An Investigational Allogeneic CAR T Product Developed Specifically For Autoimmune Diseases, In The Journal 'Nature Communications'

Reported Earlier, Allogene Therapeutics Prices 87.5M Common Shares At $2.00 Per Share In $175M Public Offering